Insulin-like growth factors and cancer - PubMed (original) (raw)

Review

Insulin-like growth factors and cancer

Gregor Fürstenberger et al. Lancet Oncol. 2002 May.

Abstract

Interest in insulin-like growth factors (IGFs) and their effect on carcinogenesis has increased recently because high serum concentrations of IGF1 are associated with an increased risk of breast, prostate, colorectal, and lung cancers. Physiologically, IGF1 is the major mediator of the effects of the growth hormone; it thus has a strong influence on cell proliferation and differentiation and is a potent inhibitor of apoptosis. The action of IGF1 is predominantly mediated through the IGF1 receptor (IGF1R). IGF1R is involved in several oncogenic transformation processes. The availability of unbound IGF1 for interaction with IGF1R is modulated by IGF-binding proteins (IGFBP1-6). IGFBPs, especially IGFBP3, have independent effects on cell growth, for example, IGFBP3 has proapoptotic activities both dependent on and independent of p53.

PubMed Disclaimer

Similar articles

• Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.
  Grimberg A, Cohen P. Grimberg A, et al. J Cell Physiol. 2000 Apr;183(1):1-9. doi: 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J. J Cell Physiol. 2000. PMID: 10699960 Free PMC article. Review.
• An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
  Fujita M, Ieguchi K, Cedano-Prieto DM, Fong A, Wilkerson C, Chen JQ, Wu M, Lo SH, Cheung AT, Wilson MD, Cardiff RD, Borowsky AD, Takada YK, Takada Y. Fujita M, et al. J Biol Chem. 2013 Jul 5;288(27):19593-603. doi: 10.1074/jbc.M113.470872. Epub 2013 May 21. J Biol Chem. 2013. PMID: 23696648 Free PMC article.
• The insulin-like growth factor system and cancer.
  LeRoith D, Roberts CT Jr. LeRoith D, et al. Cancer Lett. 2003 Jun 10;195(2):127-37. doi: 10.1016/s0304-3835(03)00159-9. Cancer Lett. 2003. PMID: 12767520 Review.
• Higher IGFBP3 is associated with increased incidence of colorectal cancer in older men independently of IGF1.
  Chan YX, Alfonso H, Paul Chubb SA, Ho KKY, Gerard Fegan P, Hankey GJ, Golledge J, Flicker L, Yeap BB. Chan YX, et al. Clin Endocrinol (Oxf). 2018 Feb;88(2):333-340. doi: 10.1111/cen.13499. Epub 2017 Nov 17. Clin Endocrinol (Oxf). 2018. PMID: 29044573
• IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
  Moody G, Beltran PJ, Mitchell P, Cajulis E, Chung YA, Hwang D, Kendall R, Radinsky R, Cohen P, Calzone FJ. Moody G, et al. J Endocrinol. 2014 Mar 17;221(1):145-55. doi: 10.1530/JOE-13-0306. Print 2014 Apr. J Endocrinol. 2014. PMID: 24492468 Free PMC article.

Cited by

• Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosis.
  Guo NL, Wan YW, Denvir J, Porter DW, Pacurari M, Wolfarth MG, Castranova V, Qian Y. Guo NL, et al. J Toxicol Environ Health A. 2012;75(18):1129-53. doi: 10.1080/15287394.2012.699852. J Toxicol Environ Health A. 2012. PMID: 22891886 Free PMC article.
• The concept of multiple hormonal dysregulation.
  Maggio M, Cattabiani C, Lauretani F, Ferrucci L, Luci M, Valenti G, Ceda G. Maggio M, et al. Acta Biomed. 2010;81 Suppl 1(Suppl 1):19-29. Acta Biomed. 2010. PMID: 20518188 Free PMC article.
• Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis.
  Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM, Chang YS. Lee CY, et al. Korean J Intern Med. 2008 Sep;23(3):116-20. doi: 10.3904/kjim.2008.23.3.116. Korean J Intern Med. 2008. PMID: 18787363 Free PMC article.
• Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.
  Kocdor H, Kocdor MA, Canda T, Gurel D, Cehreli R, Yilmaz O, Alakavuklar M, Guner G. Kocdor H, et al. Clin Transl Oncol. 2009 Apr;11(4):243-9. doi: 10.1007/s12094-009-0347-5. Clin Transl Oncol. 2009. PMID: 19380302
• Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients.
  Sıklar Z, Öcal G, Berberoğlu M, Bilir P. Sıklar Z, et al. J Clin Res Pediatr Endocrinol. 2009;1(5):240-3. doi: 10.4274/jcrpe.v1i5.240. Epub 2009 Aug 5. J Clin Res Pediatr Endocrinol. 2009. PMID: 21274301 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal